Immune drug tested before colon cancer surgery in small study
NCT ID NCT03984578
First seen Nov 18, 2025 · Last updated May 22, 2026 · Updated 18 times
Summary
This study looked at how the immune drug pembrolizumab affects colorectal cancer when given before surgery. 33 patients with non-metastatic cancer received the drug along with chemotherapy or chemoradiotherapy. The goal was to measure changes in immune activity and tumor shrinkage, not to cure the disease. It was a small, early-phase study focused on learning, not treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Centre Singapore
Singapore, 168583, Singapore
-
Sengkang General Hospital
Singapore, 544886, Singapore
-
Singapore General Hospital
Singapore, 169608, Singapore
Conditions
Explore the condition pages connected to this study.